<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;ff=20231123050859&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;ff=20231123050859&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 23 Nov 2023 10:09:00 +0000</lastbuilddate>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Potential Mechanisms of Troponin Release in Stable Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993208/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):e217. doi: 10.1016/j.jacc.2023.09.816.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993208/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993208</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.816>10.1016/j.jacc.2023.09.816</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993208</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ryan Wereski</dc:creator>
<dc:creator>Andrew R Chapman</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Potential Mechanisms of Troponin Release in Stable Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37993208</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.816</dc:identifier>
</item>
<item>
<title>Potential Mechanisms of Troponin Release in Stable Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):e215. doi: 10.1016/j.jacc.2023.08.060.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993207</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.060>10.1016/j.jacc.2023.08.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993207</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ramdas G Pai</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Potential Mechanisms of Troponin Release in Stable Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37993207</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.060</dc:identifier>
</item>
<item>
<title>Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>There is growing evidence that the atherosclerotic process that leads to symptomatic cardiovascular disease (CVD) starts at an early age. In young adults, exposure to low-density lipoprotein-cholesterol and other cardiovascular risk factor (CVRF) mediators, even at levels considered within normal limits, increases the prevalence of subclinical atherosclerosis and is associated with greater risk of cardiovascular events later in life. The optimal CVRF targets to prevent CVD in asymptomatic young...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2152-2162. doi: 10.1016/j.jacc.2023.09.817.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There is growing evidence that the atherosclerotic process that leads to symptomatic cardiovascular disease (CVD) starts at an early age. In young adults, exposure to low-density lipoprotein-cholesterol and other cardiovascular risk factor (CVRF) mediators, even at levels considered within normal limits, increases the prevalence of subclinical atherosclerosis and is associated with greater risk of cardiovascular events later in life. The optimal CVRF targets to prevent CVD in asymptomatic young individuals (&lt;40 years) are unknown. The randomized controlled PRECAD (Prevent Coronary Artery Disease) trial has been developed to assess the potential benefit of an aggressive control of CVRF in otherwise healthy young adults. The hypothesis of PRECAD is that in subjects aged 20 to 39 years without known CVD, maintaining low-density lipoprotein-cholesterol &lt;70 mg/dL and strict control of blood pressure and glucose will prevent the onset of atherosclerosis and/or its progression. The primary endpoint will be the change in total atherosclerosis burden, a surrogate for CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993206</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.817>10.1016/j.jacc.2023.09.817</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993206</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ana Devesa</dc:creator>
<dc:creator>Borja Ibanez</dc:creator>
<dc:creator>Waqas A Malick</dc:creator>
<dc:creator>Elizabeth O Tinuoye</dc:creator>
<dc:creator>Jessica Bustamante</dc:creator>
<dc:creator>Carlos Peyra</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37993206</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.817</dc:identifier>
</item>
<item>
<title>Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993205/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>Derangements in the innate and adaptive immune responses observed in systemic inflammatory syndromes contributes to unique elevated atherosclerotic risk and incident cardiovascular disease. Novel multimodality imaging techniques may improve diagnostic precision for the screening and monitoring of disease activity. The integrated application of these technologies lead to earlier diagnosis and noninvasive monitoring of cardiac involvement in systemic inflammatory diseases that will aid in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2128-2151. doi: 10.1016/j.jacc.2023.09.819.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Derangements in the innate and adaptive immune responses observed in systemic inflammatory syndromes contributes to unique elevated atherosclerotic risk and incident cardiovascular disease. Novel multimodality imaging techniques may improve diagnostic precision for the screening and monitoring of disease activity. The integrated application of these technologies lead to earlier diagnosis and noninvasive monitoring of cardiac involvement in systemic inflammatory diseases that will aid in preclinical studies, enhance patient selection, and provide surrogate endpoints in clinical trials, thereby improving clinical outcomes. We review the common cardiovascular manifestations of immune-mediated systemic inflammatory diseases and address the clinical and investigational role of advanced multimodality cardiac imaging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993205/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993205</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.819>10.1016/j.jacc.2023.09.819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993205</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Julie J Paik</dc:creator>
<dc:creator>Ayaz Aghayev</dc:creator>
<dc:creator>Allan L Klein</dc:creator>
<dc:creator>Sophie I Mavrogeni</dc:creator>
<dc:creator>Paul B Yu</dc:creator>
<dc:creator>Monica Mukherjee</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:37993205</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.819</dc:identifier>
</item>
<item>
<title>Learning From Machines to Predict Mortality After Surgical or Percutaneous Revascularization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2125-2127. doi: 10.1016/j.jacc.2023.10.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993204</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.002>10.1016/j.jacc.2023.10.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993204</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Paul A Kurlansky</dc:creator>
<dc:creator>John A Bittl</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Learning From Machines to Predict Mortality After Surgical or Percutaneous Revascularization</dc:title>
<dc:identifier>pmid:37993204</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.002</dc:identifier>
</item>
<item>
<title>Can Machine Learning Aid the Selection of Percutaneous vs Surgical Revascularization?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993203/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: An ML-based approach for identifying individuals who benefit from CABG or PCI is feasible and effective. Implementation of this model in health care systems-trained to collect large numbers of parameters-may harmonize decision making globally. (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYNTAXES]; NCT03417050; SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries; NCT00114972).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2113-2124. doi: 10.1016/j.jacc.2023.09.818.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with 3-vessel coronary artery disease (CAD) and/or left main CAD, individual risk prediction plays a key role in deciding between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to assess whether these individualized revascularization decisions can be improved by applying machine learning (ML) algorithms and integrating clinical, biological, and anatomical factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) study, ML algorithms (Lasso regression, gradient boosting) were used to develop a prognostic index for 5-year death, which was combined, in the second stage, with assigned treatment (PCI or CABG) and prespecified effect-modifiers: disease type (3-vessel or left main CAD) and anatomical SYNTAX score. The model's discriminative ability to predict the risk of 5-year death and treatment benefit between PCI and CABG was cross-validated in the SYNTAX trial (n = 1,800) and externally validated in the CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome Study in Kyoto) registry (n = 7,362), and then compared with the original SYNTAX score II 2020 (SSII-2020).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The hybrid gradient boosting model performed best for predicting 5-year all-cause death with C-indexes of 0.78 (95% CI: 0.75-0.81) in cross-validation and 0.77 (95% CI: 0.76-0.79) in external validation. The ML models discriminated 5-year mortality better than the SSII-2020 in the external validation cohort and identified heterogeneity in the treatment benefit of CABG vs PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: An ML-based approach for identifying individuals who benefit from CABG or PCI is feasible and effective. Implementation of this model in health care systems-trained to collect large numbers of parameters-may harmonize decision making globally. (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYNTAXES]; NCT03417050; SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries; NCT00114972).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993203/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993203</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.818>10.1016/j.jacc.2023.09.818</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993203</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kai Ninomiya</dc:creator>
<dc:creator>Shigetaka Kageyama</dc:creator>
<dc:creator>Hiroki Shiomi</dc:creator>
<dc:creator>Nozomi Kotoku</dc:creator>
<dc:creator>Shinichiro Masuda</dc:creator>
<dc:creator>Pruthvi C Revaiah</dc:creator>
<dc:creator>Scot Garg</dc:creator>
<dc:creator>Neil O'Leary</dc:creator>
<dc:creator>David van Klaveren</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Yoshinobu Onuma</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>SYNTAX Investigators</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Can Machine Learning Aid the Selection of Percutaneous vs Surgical Revascularization?</dc:title>
<dc:identifier>pmid:37993203</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.818</dc:identifier>
</item>
<item>
<title>Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2097-2100. doi: 10.1016/j.jacc.2023.09.812. Epub 2023 Oct 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993202</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.812>10.1016/j.jacc.2023.09.812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993202</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>John W Ostrominski</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide</dc:title>
<dc:identifier>pmid:37993202</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.812</dc:identifier>
</item>
<item>
<title>Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with HFpEF and obesity, semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight to a similar extent across LVEF categories. These data support treatment with semaglutide in patients with the obesity phenotype of HFpEF regardless of LVEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2087-2096. doi: 10.1016/j.jacc.2023.09.811. Epub 2023 Oct 8.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Many therapies for heart failure (HF) have shown differential impact across the spectrum of left ventricular ejection fraction (LVEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this prespecified analysis, the authors assessed the effects of semaglutide across the baseline LVEF strata in patients with the obesity phenotype of HF with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: STEP-HFpEF randomized 529 patients (263 semaglutide; 266 placebo). For this prespecified analysis, patients were categorized into 3 groups based on LVEF: 45% to 49% (n = 85), 50% to 59% (n = 215), and ≥60% (n = 229).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 52 weeks, semaglutide improved the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (estimated treatment difference: EF [ejection fraction] 45%-49%: 5.0 points [95% CI: -2.7 to 12.8 points], EF 50%-59%: 9.8 points [95% CI: 5.0 to 14.6 points], and EF ≥60%: 7.4 points [95% CI: 2.8 to 12.0 points]; P interaction = 0.56) and body weight (EF: 45%-49%: -7.6 [95% CI: -10.7 to -4.4], EF 50%-59%: -10.6 [95% CI: -12.6 to -8.6] and EF ≥60%: -11.9 [95% CI: -13.8 to -9.9]; P interaction = 0.08), to a similar extent across LVEF categories. Likewise, LVEF did not influence the benefit of semaglutide on confirmatory secondary endpoints: 6-minute walk distance (P interaction = 0.19), hierarchal composite endpoint (P interaction = 0.43), and high-sensitivity C-reactive protein (P interaction = 0.26); or exploratory endpoint of N-terminal pro-brain natriuretic peptide (P interaction = 0.96). Semaglutide was well-tolerated across LVEF categories.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFpEF and obesity, semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight to a similar extent across LVEF categories. These data support treatment with semaglutide in patients with the obesity phenotype of HFpEF regardless of LVEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993201</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.811>10.1016/j.jacc.2023.09.811</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993201</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Steen Z Abildstrøm</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Melanie J Davies</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Walter P Abhayaratna</dc:creator>
<dc:creator>Vijay Chopra</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Michael Fu</dc:creator>
<dc:creator>Hiroshi Ito</dc:creator>
<dc:creator>Małgorzata Lelonek</dc:creator>
<dc:creator>Julio Núñez</dc:creator>
<dc:creator>Eduardo Perna</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Dirk von Lewinski</dc:creator>
<dc:creator>Dennis Wolf</dc:creator>
<dc:creator>Rebecca L Altschul</dc:creator>
<dc:creator>Søren Rasmussen</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:37993201</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.811</dc:identifier>
</item>
<item>
<title>Charting a Course for Atherosclerosis Regression: Shifting the Paradigm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993200/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2084-2086. doi: 10.1016/j.jacc.2023.10.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993200/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993200</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.003>10.1016/j.jacc.2023.10.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993200</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Charles A German</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Charting a Course for Atherosclerosis Regression: Shifting the Paradigm</dc:title>
<dc:identifier>pmid:37993200</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.003</dc:identifier>
</item>
<item>
<title>Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993199/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Over 6 years, subclinical atherosclerosis progressed in one-third of middle-age asymptomatic subjects. Atherosclerosis regression is possible in early stages of the disease. The impact of LDL-C and SBP on subclinical atherosclerosis progression was more pronounced in younger participants, a finding suggesting that the prevention of atherosclerosis and its progression could be enhanced by tighter risk factor control at younger ages, with a likely long-term impact on reducing the risk...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2069-2083. doi: 10.1016/j.jacc.2023.09.814.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atherosclerosis is a systemic disease that frequently begins early in life. However, knowledge about the temporal disease dynamics (ie, progression or regression) of human subclinical atherosclerosis and their determinants is scarce.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to investigate early subclinical atherosclerosis disease dynamics within a cohort of middle-aged, asymptomatic individuals by using multiterritorial 3-dimensional vascular ultrasound (3DVUS) imaging.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 3,471 participants from the PESA (Progression of Early Subclinical Atherosclerosis) cohort study (baseline age 40-55 years; 36% female) underwent 3 serial 3DVUS imaging assessments of peripheral arteries at 3-year intervals. Subclinical atherosclerosis was quantified as global plaque volume (mm<sup>3</sup>) (bilateral carotid and femoral plaque burden). Multivariable logistic regression models for progression and regression were developed using stepwise forward variable selection.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Baseline to 6-year subclinical atherosclerosis progression occurred in 32.7% of the cohort (17.5% presenting with incident disease and 15.2% progressing from prevalent disease at enrollment). Regression was observed in 8.0% of those patients with baseline disease. The effects of higher low-density lipoprotein cholesterol (LDL-C) and elevated systolic blood pressure (SBP) on 6-year subclinical atherosclerosis progression risk were more pronounced among participants in the youngest age stratum (P<sub>interaction</sub> = 0.04 and 0.02, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Over 6 years, subclinical atherosclerosis progressed in one-third of middle-age asymptomatic subjects. Atherosclerosis regression is possible in early stages of the disease. The impact of LDL-C and SBP on subclinical atherosclerosis progression was more pronounced in younger participants, a finding suggesting that the prevention of atherosclerosis and its progression could be enhanced by tighter risk factor control at younger ages, with a likely long-term impact on reducing the risk of clinical events. (Progression of Early Subclinical Atherosclerosis [PESA; also PESA-CNIC-Santander]; NCT01410318).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993199/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37993199</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.814>10.1016/j.jacc.2023.09.814</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993199</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Guiomar Mendieta</dc:creator>
<dc:creator>Stuart Pocock</dc:creator>
<dc:creator>Virginia Mass</dc:creator>
<dc:creator>Andrea Moreno</dc:creator>
<dc:creator>Ruth Owen</dc:creator>
<dc:creator>Inés García-Lunar</dc:creator>
<dc:creator>Beatriz López-Melgar</dc:creator>
<dc:creator>Jose J Fuster</dc:creator>
<dc:creator>Vicente Andres</dc:creator>
<dc:creator>Cristina Pérez-Herreras</dc:creator>
<dc:creator>Hector Bueno</dc:creator>
<dc:creator>Antonio Fernández-Ortiz</dc:creator>
<dc:creator>Javier Sanchez-Gonzalez</dc:creator>
<dc:creator>Ana García-Alvarez</dc:creator>
<dc:creator>Borja Ibáñez</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years</dc:title>
<dc:identifier>pmid:37993199</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.814</dc:identifier>
</item>
<item>
<title>Glycosylated queuosines in tRNAs optimize translational rate and post-embryonic growth</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37992713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>Transfer RNA (tRNA) modifications are critical for protein synthesis. Queuosine (Q), a 7-deaza-guanosine derivative, is present in tRNA anticodons. In vertebrate tRNAs for Tyr and Asp, Q is further glycosylated with galactose and mannose to generate galQ and manQ, respectively. However, biogenesis and physiological relevance of Q-glycosylation remain poorly understood. Here, we biochemically identified two RNA glycosylases, QTGAL and QTMAN, and successfully reconstituted Q-glycosylation of tRNAs...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 17:S0092-8674(23)01177-7. doi: 10.1016/j.cell.2023.10.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transfer RNA (tRNA) modifications are critical for protein synthesis. Queuosine (Q), a 7-deaza-guanosine derivative, is present in tRNA anticodons. In vertebrate tRNAs for Tyr and Asp, Q is further glycosylated with galactose and mannose to generate galQ and manQ, respectively. However, biogenesis and physiological relevance of Q-glycosylation remain poorly understood. Here, we biochemically identified two RNA glycosylases, QTGAL and QTMAN, and successfully reconstituted Q-glycosylation of tRNAs using nucleotide diphosphate sugars. Ribosome profiling of knockout cells revealed that Q-glycosylation slowed down elongation at cognate codons, UAC and GAC (GAU), respectively. We also found that galactosylation of Q suppresses stop codon readthrough. Moreover, protein aggregates increased in cells lacking Q-glycosylation, indicating that Q-glycosylation contributes to proteostasis. Cryo-EM of human ribosome-tRNA complex revealed the molecular basis of codon recognition regulated by Q-glycosylations. Furthermore, zebrafish qtgal and qtman knockout lines displayed shortened body length, implying that Q-glycosylation is required for post-embryonic growth in vertebrates.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37992713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37992713</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.026>10.1016/j.cell.2023.10.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37992713</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Xuewei Zhao</dc:creator>
<dc:creator>Ding Ma</dc:creator>
<dc:creator>Kensuke Ishiguro</dc:creator>
<dc:creator>Hironori Saito</dc:creator>
<dc:creator>Shinichiro Akichika</dc:creator>
<dc:creator>Ikuya Matsuzawa</dc:creator>
<dc:creator>Mari Mito</dc:creator>
<dc:creator>Toru Irie</dc:creator>
<dc:creator>Kota Ishibashi</dc:creator>
<dc:creator>Kimi Wakabayashi</dc:creator>
<dc:creator>Yuriko Sakaguchi</dc:creator>
<dc:creator>Takeshi Yokoyama</dc:creator>
<dc:creator>Yuichiro Mishima</dc:creator>
<dc:creator>Mikako Shirouzu</dc:creator>
<dc:creator>Shintaro Iwasaki</dc:creator>
<dc:creator>Takeo Suzuki</dc:creator>
<dc:creator>Tsutomu Suzuki</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Glycosylated queuosines in tRNAs optimize translational rate and post-embryonic growth</dc:title>
<dc:identifier>pmid:37992713</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.026</dc:identifier>
</item>
<item>
<title>The activator protein-1 complex governs a vascular degenerative transcriptional programme in smooth muscle cells to trigger aortic dissection and rupture</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37992083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This cross-sectional compendium of cellular atlas of human ascending aortas during AD progression provides previously unappreciated insights into a transcriptional programme permitting aortic degeneration, highlighting a translational proof of concept for an anti-remodelling intervention as an attractive strategy to manage temporal-specific AD by modulating the tumour necrosis factor-OXPHOS-AP-1 axis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 22:ehad534. doi: 10.1093/eurheartj/ehad534. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Stanford type A aortic dissection (AD) is a degenerative aortic remodelling disease marked by an exceedingly high mortality without effective pharmacologic therapies. Smooth muscle cells (SMCs) lining tunica media adopt a range of states, and their transformation from contractile to synthetic phenotypes fundamentally triggers AD. However, the underlying pathomechanisms governing this population shift and subsequent AD, particularly at distinct disease temporal stages, remain elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Ascending aortas from nine patients undergoing ascending aorta replacement and five individuals undergoing heart transplantation were subjected to single-cell RNA sequencing. The pathogenic targets governing the phenotypic switch of SMCs were identified by trajectory inference, functional scoring, single-cell regulatory network inference and clustering, regulon, and interactome analyses and confirmed using human ascending aortas, primary SMCs, and a β-aminopropionitrile monofumarate-induced AD model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The transcriptional profiles of 93 397 cells revealed a dynamic temporal-specific phenotypic transition and marked elevation of the activator protein-1 (AP-1) complex, actively enabling synthetic SMC expansion. Mechanistically, tumour necrosis factor signalling enhanced AP-1 transcriptional activity by dampening mitochondrial oxidative phosphorylation (OXPHOS). Targeting this axis with the OXPHOS enhancer coenzyme Q10 or AP-1-specific inhibitor T-5224 impedes phenotypic transition and aortic degeneration while improving survival by 42.88% (58.3%-83.3% for coenzyme Q10 treatment), 150.15% (33.3%-83.3% for 2-week T-5224), and 175.38% (33.3%-91.7% for 3-week T-5224) in the β-aminopropionitrile monofumarate-induced AD model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This cross-sectional compendium of cellular atlas of human ascending aortas during AD progression provides previously unappreciated insights into a transcriptional programme permitting aortic degeneration, highlighting a translational proof of concept for an anti-remodelling intervention as an attractive strategy to manage temporal-specific AD by modulating the tumour necrosis factor-OXPHOS-AP-1 axis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37992083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37992083</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad534>10.1093/eurheartj/ehad534</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37992083</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yongting Luo</dc:creator>
<dc:creator>Junjie Luo</dc:creator>
<dc:creator>Peng An</dc:creator>
<dc:creator>Yuanfei Zhao</dc:creator>
<dc:creator>Wenting Zhao</dc:creator>
<dc:creator>Zhou Fang</dc:creator>
<dc:creator>Yi Xia</dc:creator>
<dc:creator>Lin Zhu</dc:creator>
<dc:creator>Teng Xu</dc:creator>
<dc:creator>Xu Zhang</dc:creator>
<dc:creator>Shuaishuai Zhou</dc:creator>
<dc:creator>Mingyan Yang</dc:creator>
<dc:creator>Jiayao Li</dc:creator>
<dc:creator>Junming Zhu</dc:creator>
<dc:creator>Yongmin Liu</dc:creator>
<dc:creator>Haiyang Li</dc:creator>
<dc:creator>Ming Gong</dc:creator>
<dc:creator>Yuyong Liu</dc:creator>
<dc:creator>Jie Han</dc:creator>
<dc:creator>Huiyuan Guo</dc:creator>
<dc:creator>Hongjia Zhang</dc:creator>
<dc:creator>Wenjian Jiang</dc:creator>
<dc:creator>Fazheng Ren</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The activator protein-1 complex governs a vascular degenerative transcriptional programme in smooth muscle cells to trigger aortic dissection and rupture</dc:title>
<dc:identifier>pmid:37992083</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad534</dc:identifier>
</item>
<item>
<title>High-Sensitivity Troponin in Pulmonary Embolism Risk Stratification-Proceed With Caution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 22. doi: 10.1001/jamacardio.2023.4363. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37991786</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4363>10.1001/jamacardio.2023.4363</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991786</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Vinay Guduguntla</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>High-Sensitivity Troponin in Pulmonary Embolism Risk Stratification-Proceed With Caution</dc:title>
<dc:identifier>pmid:37991786</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4363</dc:identifier>
</item>
<item>
<title>High-Sensitivity vs Conventional Troponin Cutoffs for Risk Stratification in Patients With Acute Pulmonary Embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991780/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this study of patients with hemodynamically stable PE, hs-cTnI identified modest elevations in cardiac troponin levels. However, the results did not provide additive clinical value compared with cTnI. These findings suggest that use of hs-cTnI may result in overestimation of the risk in patients with stable PE.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 22. doi: 10.1001/jamacardio.2023.4356. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: High-sensitivity troponin tests can detect even milder cardiac troponin elevations in plasma, beyond the threshold of conventional troponin tests. Whether detection of low-grade cardiac troponin elevation is associated with outcomes of patients with hemodynamically stable pulmonary embolism (PE) and helps with risk stratification is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the association between high-sensitivity cardiac troponin I (hs-cTnI) compared with conventional cardiac troponin I (cTnI) and PE risk designations according to the European Society of Cardiology (ESC) 2019 classification scheme and clinical outcomes in patients with hemodynamically stable PE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc analysis of data from the prospective Prognostic Value of Computed Tomography (PROTECT) multicenter cohort study enrolling patients from 12 hospital emergency departments in Spain. In this analysis, cTnI and hs-cTnI were compared with respect to ESC risk designation, and the association between troponin values and a complicated course after PE diagnosis was evaluated. Of 848 patients enrolled in PROTECT, 834 (98.3%) had hsTnI and cTnI values available and were included in the present analysis. Data were analyzed from May to December 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Troponin blood testing with cTnI (threshold of >;0.05 ng/mL) vs hs-cTnI (threshold of >;0.029 ng/mL) assays at the time of PE diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES: Complicated course, defined as hemodynamic collapse, recurrent PE, or all-cause death, within 30 days after PE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 834 patients (mean [SEM] age, 67.5 [0.6] years; 424 [50.8%] female), 139 (16.7%) had elevated cTnI and 264 (31.7%) elevated hs-TnI, respectively. During follow-up, 62 patients (7.4%; 95% CI, 5.7-9.4) had a complicated course. Analyzing troponin elevation as a binary variable, elevated cTnI (odds ratio [OR], 2.84; 95% CI, 1.62-4.98) but not hs-cTnI (OR, 1.12; 95% CI, 0.65-1.93) was associated with increased odds of a complicated course. Of 125 patients who had elevated hs-cTnI but normal cTnI, none (0; 95% CI, 0.0-2.9) developed a complicated course. Using the 2019 ESC risk stratification scheme, hs-TnI classified fewer patients as low risk compared with cTnI. Among 78 patients designated as ESC low risk when using cTnI but not with hsTnI, none (0; 95% CI, 0.0-4.6) had a complicated course.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study of patients with hemodynamically stable PE, hs-cTnI identified modest elevations in cardiac troponin levels. However, the results did not provide additive clinical value compared with cTnI. These findings suggest that use of hs-cTnI may result in overestimation of the risk in patients with stable PE.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991780/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37991780</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4356>10.1001/jamacardio.2023.4356</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991780</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Alfonso Muriel</dc:creator>
<dc:creator>Carmen Rodríguez</dc:creator>
<dc:creator>Sara González</dc:creator>
<dc:creator>Winnifer Briceño</dc:creator>
<dc:creator>Ghazaleh Mehdipoor</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:creator>Aitor Ballaz</dc:creator>
<dc:creator>Giuseppe Lippi</dc:creator>
<dc:creator>Roger D Yusen</dc:creator>
<dc:creator>Remedios Otero</dc:creator>
<dc:creator>David Jiménez</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>High-Sensitivity vs Conventional Troponin Cutoffs for Risk Stratification in Patients With Acute Pulmonary Embolism</dc:title>
<dc:identifier>pmid:37991780</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4356</dc:identifier>
</item>
<item>
<title>We Matched</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991769/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 22. doi: 10.1001/jamacardio.2023.4254. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991769/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37991769</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4254>10.1001/jamacardio.2023.4254</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991769</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Katia Bravo-Jaimes</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>We Matched</dc:title>
<dc:identifier>pmid:37991769</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4254</dc:identifier>
</item>
<item>
<title>Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991745/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: These findings suggest that women with HBR did not experience higher rates of ischemic or bleeding events compared with men and may derive particular benefit from abbreviated compared with standard DAPT owing to these numerically lower rates of events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 22. doi: 10.1001/jamacardio.2023.4316. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PATIENTS: This prespecified subgroup comparative effectiveness analysis followed the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated vs Standard DAPT Regimen (MASTER DAPT) trial, a multicenter, randomized, open-label clinical trial conducted at 140 sites in 30 countries and performed from February 28, 2017, to December 5, 2019. A total of 4579 patients with HBR were randomized at 1 month after PCI to abbreviated or standard DAPT. Data were analyzed from July 1 to October 31, 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Abbreviated (immediate DAPT discontinuation, followed by single APT for ≥6 months) or standard (DAPT for ≥2 additional months, followed by single APT for 11 months) treatment groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: One-year net adverse clinical events (NACEs) (a composite of death due to any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (MACCEs) (a composite of death due to any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding (MCB).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 4579 patients included in the analysis, 1408 (30.7%) were women and 3171 (69.3%) were men (mean [SD] age, 76.0 [8.7] years). Ischemic and bleeding events were similar between sexes. Abbreviated DAPT was associated with comparable NACE rates in men (hazard ratio [HR], 0.97 [95% CI, 0.75-1.24]) and women (HR, 0.87 [95% CI, 0.60-1.26]; P = .65 for interaction). There was evidence of heterogeneity of treatment effect by sex for MACCEs, with a trend toward benefit in women (HR, 0.68 [95% CI, 0.44-1.05]) but not in men (HR, 1.17 [95% CI, 0.88-1.55]; P = .04 for interaction). There was no significant interaction for MCB across sex, although the benefit with abbreviated DAPT was relatively greater in men (HR, 0.65 [95% CI, 0.50-0.84]) than in women (HR, 0.77 [95% CI, 0.53-1.12]; P = .46 for interaction). Results remained consistent in patients with acute coronary syndrome and/or complex PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: These findings suggest that women with HBR did not experience higher rates of ischemic or bleeding events compared with men and may derive particular benefit from abbreviated compared with standard DAPT owing to these numerically lower rates of events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03023020.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991745/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37991745</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4316>10.1001/jamacardio.2023.4316</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991745</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Antonio Landi</dc:creator>
<dc:creator>Mirvat Alasnag</dc:creator>
<dc:creator>Dik Heg</dc:creator>
<dc:creator>Enrico Frigoli</dc:creator>
<dc:creator>Fazila Tun Nesa Malik</dc:creator>
<dc:creator>Ivan Gomez-Blazquez</dc:creator>
<dc:creator>Suzanne Pourbaix</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Christian Spaulding</dc:creator>
<dc:creator>Fermin Sainz</dc:creator>
<dc:creator>Helen Routledge</dc:creator>
<dc:creator>Giuseppe Andò</dc:creator>
<dc:creator>Luca Testa</dc:creator>
<dc:creator>Alessandro Sciahbasi</dc:creator>
<dc:creator>Hussain Contractor</dc:creator>
<dc:creator>Nigel Jepson</dc:creator>
<dc:creator>Juan Mieres</dc:creator>
<dc:creator>Syed Saqib Imran</dc:creator>
<dc:creator>Husam Noor</dc:creator>
<dc:creator>Pieter C Smits</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>MASTER DAPT Investigators</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37991745</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4316</dc:identifier>
</item>
<item>
<title>AfricaSTEMI Live! 2023-a unique learning experience</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 22:ehad767. doi: 10.1093/eurheartj/ehad767. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37991437</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad767>10.1093/eurheartj/ehad767</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991437</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Habib Gamra</dc:creator>
<dc:creator>Bernard Gersh</dc:creator>
<dc:creator>Mohamed Jeilan</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>AfricaSTEMI Live! 2023-a unique learning experience</dc:title>
<dc:identifier>pmid:37991437</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad767</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37989571/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 22:ehad774. doi: 10.1093/eurheartj/ehad774. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37989571/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37989571</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad774>10.1093/eurheartj/ehad774</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37989571</guid>
<pubDate>Tue, 21 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)</dc:title>
<dc:identifier>pmid:37989571</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad774</dc:identifier>
</item>
<item>
<title>Parallel neural pathways control sodium consumption and taste valence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37989313/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>The hedonic value of salt fundamentally changes depending on the internal state. High concentrations of salt induce innate aversion under sated states, whereas such aversive stimuli transform into appetitive ones under sodium depletion. Neural mechanisms underlying this state-dependent salt valence switch are poorly understood. Using transcriptomics state-to-cell-type mapping and neural manipulations, we show that positive and negative valences of salt are controlled by anatomically distinct...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 17:S0092-8674(23)01171-6. doi: 10.1016/j.cell.2023.10.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The hedonic value of salt fundamentally changes depending on the internal state. High concentrations of salt induce innate aversion under sated states, whereas such aversive stimuli transform into appetitive ones under sodium depletion. Neural mechanisms underlying this state-dependent salt valence switch are poorly understood. Using transcriptomics state-to-cell-type mapping and neural manipulations, we show that positive and negative valences of salt are controlled by anatomically distinct neural circuits in the mammalian brain. The hindbrain interoceptive circuit regulates sodium-specific appetitive drive , whereas behavioral tolerance of aversive salts is encoded by a dedicated class of neurons in the forebrain lamina terminalis (LT) expressing prostaglandin E2 (PGE2) receptor, Ptger3. We show that these LT neurons regulate salt tolerance by selectively modulating aversive taste sensitivity, partly through a PGE2-Ptger3 axis. These results reveal the bimodal regulation of appetitive and tolerance signals toward salt, which together dictate the amount of sodium consumption under different internal states.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37989313/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37989313</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.020>10.1016/j.cell.2023.10.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37989313</guid>
<pubDate>Tue, 21 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yameng Zhang</dc:creator>
<dc:creator>Allan-Hermann Pool</dc:creator>
<dc:creator>Tongtong Wang</dc:creator>
<dc:creator>Lu Liu</dc:creator>
<dc:creator>Elin Kang</dc:creator>
<dc:creator>Bei Zhang</dc:creator>
<dc:creator>Liang Ding</dc:creator>
<dc:creator>Kirsten Frieda</dc:creator>
<dc:creator>Richard Palmiter</dc:creator>
<dc:creator>Yuki Oka</dc:creator>
<dc:date>2023-11-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Parallel neural pathways control sodium consumption and taste valence</dc:title>
<dc:identifier>pmid:37989313</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.020</dc:identifier>
</item>
<item>
<title>Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37985696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>The surge in reports describing non-coding RNAs (ncRNAs) has focused attention on their possible biological roles and effects on development and disease. ncRNAs have been touted as previously uncharacterized regulators of gene expression and cellular processes, possibly working to fine-tune these functions. The sheer number of ncRNAs identified has outpaced the capacity to characterize each molecule thoroughly and to reliably establish its clinical relevance; it has, nonetheless, created...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 20. doi: 10.1038/s41569-023-00952-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The surge in reports describing non-coding RNAs (ncRNAs) has focused attention on their possible biological roles and effects on development and disease. ncRNAs have been touted as previously uncharacterized regulators of gene expression and cellular processes, possibly working to fine-tune these functions. The sheer number of ncRNAs identified has outpaced the capacity to characterize each molecule thoroughly and to reliably establish its clinical relevance; it has, nonetheless, created excitement about their potential as molecular targets for novel therapeutic approaches to treat human disease. In this Review, we focus on one category of ncRNAs - long non-coding RNAs - and their expression, functions and molecular mechanisms in cardiac hypertrophy and heart failure. We further discuss the prospects for this specific class of ncRNAs as novel targets for the diagnosis and treatment of these conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37985696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37985696</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00952-5>10.1038/s41569-023-00952-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37985696</guid>
<pubDate>Tue, 21 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>John D Mably</dc:creator>
<dc:creator>Da-Zhi Wang</dc:creator>
<dc:date>2023-11-21</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects</dc:title>
<dc:identifier>pmid:37985696</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00952-5</dc:identifier>
</item>
<item>
<title>Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37985192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231123050859&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 21;44(44):4607-4611. doi: 10.1093/eurheartj/ehad765.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37985192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231123050859&v=2.17.9.post6+86293ac">37985192</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad765>10.1093/eurheartj/ehad765</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37985192</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets</dc:title>
<dc:identifier>pmid:37985192</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad765</dc:identifier>
</item>





























</channel>
</rss>